Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-24-128115
Filing Date
2024-11-18
Accepted
2024-11-18 17:45:50
Documents
1
Period of Report
2024-11-14

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3467
  Complete submission text file 0000950170-24-128115.txt   4970
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Issuer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O VANDA PHARMACEUTICALS INC. 2200 PENNSYLVANIA AVE., SUITE 300E WASHINGTON DC 20037
Business Address
Mitchell Stephen Ray (Reporting) CIK: 0001802653 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34186 | Film No.: 241472629